



35997-Review.docx

 Quotes Excluded  
 Bibliography Excluded

 15%  
 SIMILAR

 Name of Journal: *World Journal of Hepatology*

Manuscript NO: 35997

Manuscript Type: Original Article

*Retrospective Cohort Study*

**11** Efficacy and safety of sofosbuvir and ledipasvir in japanese patients aged 75 years or over with hepatitis C

Yoshinori Ozono, Kenji Nagata, Satoru Hasuike, Hisayoshi Iwakiri, Kenichi Nakamura, Mai Tsuchimochi, Yuka Takaishi, Mitsue Sueta, Tadashi Miike, Yoshihiro Tahara, Shojiro Yamamoto, Kotaro Shide, Tomo Yoko Kubuki, **3** Kazunori Kusumoto, Toshimasa Ochiai, Junya Kato, Naoto Komada, Shuichi Hirono, K Masafumi Shigehira and Kazuya Shimoda

Abstract

## Match Overview

1	<b>Internet</b> 82 words crawled on 24-Sep-2017 <a href="http://www.omicsonline.org">www.omicsonline.org</a>	4%
2	<b>Crossref</b> 40 words Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen et al. "NS5A resistance-associated variants und	2%
3	<b>Crossref</b> 30 words "Poster Session IV (Abstracts 1638 - 2112)", Hepatology, 2016	1%
4	<b>Crossref</b> 23 words Saab, Sammy, Sarah H. Park, Masashi Mizokami, Masao Omata, Alessandra Mangia, Ed Eggleton, Yanni Zhu, Steven	1%
5	<b>Publications</b> 19 words Iguchi, Naoya Uchiyama, Akinori Ueta, Ka. "Neutrophil gelatinase-associated lipocalin and liver-type fatty acid-bindin...	1%
6	<b>Crossref</b> 16 words Michele Malaguamera. "The Supplementation of Acetyl-L-Carnitine Decreases Fatigue and Increases Quality of Life in	1%

找到约 10,500 条结果 (用时 0.53 秒)

### [PDF] Safety and efficacy of ledipasvir/sofosbuvir for the treatment ... - NATAP

[www.natap.org/2017/EASL/hep28425.pdf](http://www.natap.org/2017/EASL/hep28425.pdf)  翻译此页

作者 : SJ Knox - 2016 - 被引用次数 : 19 - 相关文章

Safety and Efficacy of Ledipasvir/ Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years or Older. Sammy Saab,1 Sarah H. Park,1 ...

### Ledipasvir and sofosbuvir fixed-dose combination with and without ...

<https://www.ncbi.nlm.nih.gov/pubmed/25863559> - 翻译此页

作者 : M Mizokami - 2015 - 被引用次数 : 187 - 相关文章

2015年4月8日 - Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 ... and previously treated Japanese patients with genotype 1 hepatitis C: an ... treated for hepatitis C. We aimed to assess the efficacy and safety of an ... Eligible patients were at least 20 years of age with chronic genotype 1 ...

### The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir ...

<https://www.hindawi.com/journals/cjgh/2017/6468309/> - 翻译此页

作者 : W Stokes - 2017 - 相关文章

2017年1月26日 - The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who ... Over 210,000 Canadians are estimated to be currently living with ... to peak between 2031 and 2035 at approximately 40,000 per year [3].

### Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin ...

[www.sciencedirect.com/science/article/pii/S120197121631668X](http://www.sciencedirect.com/science/article/pii/S120197121631668X) - 翻译此页

作者 : T Tao - 2017 - 被引用次数 : 3 - 相关文章

2016年12月29日 - Meta-analysis assessed the efficacy and safety of the LDV-SOF with and ... Seven studies involving 2 626 patients with HCV GT 1 – some of whom ... C. Approximately 500 000 people

全部 图片 视频 新闻 地图 图书

找到约 2,040 条结果

[\[PDF\] Safety and efficacy of ledipasvir/sofosbuvir for the treatment ... - NATAP](#)

[www.natap.org/2017/EASL/hep28425.pdf](http://www.natap.org/2017/EASL/hep28425.pdf)

Safety and Efficacy of Ledipasvir/ Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years or Older. Sammy Saab,1 Sarah H. Park,1 ...

[Safety and efficacy of ledipasvir/sofosbuvir for the treatment ... - NATAP](#)

[www.natap.org/2017/HCV/050317\\_03.htm](http://www.natap.org/2017/HCV/050317_03.htm)

genotype 1 hepatitis C in subjects aged 65 years or older ... 3 trials, 264 (12%) were  $\geq 65$  years of age, of whom 24 were aged  $\geq 75$  years. ... and in Japan as a fixed-dose combination tablet for the treatment of HCV genotype 1. ... Given the aging population of patients with HCV and the increased efficacy of LDV/SOF over ...

[Safety and efficacy of ledipasvir/sofosbuvir for the treatment ... - NCBI](#)

<https://www.ncbi.nlm.nih.gov/pubmed/26704693>

22 Feb 2016 ... Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years ... (2)National Center for Global Health and Medicine, Tokyo, Japan. ... Of the 2293 subjects enrolled in four phase 3 trials, 264 (12%) were  $\geq 65$  years of age, of whom 24 were aged  $\geq 75$  years.

[Ledipasvir and sofosbuvir fixed-dose combination with and without ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/25863559>

8 Apr 2015 ... Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for ... and previously treated Japanese patients with genotype 1 hepatitis C: an ... treated for hepatitis C. We aimed to assess the efficacy and safety of an ... years of age with chronic genotype 1 hepatitis C virus infection with serum ...

[Safety and efficacy of ledipasvir/sofosbuvir for the treatment of ...](#)

[onlinelibrary.wiley.com/doi/10.1002/hep.28425/full](http://onlinelibrary.wiley.com/doi/10.1002/hep.28425/full)



Efficacy and safety of sofosbuvir and ledipasvir in japanese patients aged



全部

新闻

图片

购物

地图

更多

设置

工具

找到约 2,080 条结果 (用时 0.61 秒)

### Safety and efficacy of ledipasvir/sofosbuvir for the treatment of ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/26704693> - 翻译此页

作者: S Saab - 2016 - 被引用次数: 23 - 相关文章

2016年2月22日 - Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years ... (2)National Center for Global Health and Medicine, Tokyo, Japan. ... Of the 2293 subjects enrolled in four phase 3 trials, 264 (12%) were ≥65 years of age, of whom 24 were aged ≥75 years.

### Safety and efficacy of ledipasvir/sofosbuvir for the treatment ... - NATAP

[www.natap.org/2017/EASL/hep28425.pdf](http://www.natap.org/2017/EASL/hep28425.pdf) - 翻译此页

作者: SJ Knox - 2016 - 被引用次数: 23 - 相关文章

Safety and Efficacy of Ledipasvir/ Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years or Older. Sammy Saab,1 Sarah H. Park,1 ...

### Safety and efficacy of ledipasvir/sofosbuvir for ... - Wiley Online Library

[onlinelibrary.wiley.com/doi/10.1002/hep.28425/full](http://onlinelibrary.wiley.com/doi/10.1002/hep.28425/full) - 翻译此页

作者: S Saab - 2016 - 被引用次数: 23 - 相关文章

2016年2月22日 - Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older .... in Japan as a fixed-dose combination tablet for the treatment of HCV genotype 1. .... Given the aging population of patients with HCV and the increased efficacy of LDV/SOF over prior ...

### Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin ...

[www.sciencedirect.com/science/article/pii/S120197121631668X](http://www.sciencedirect.com/science/article/pii/S120197121631668X) - 翻译此页

作者: T Tao - 2017 - 被引用次数: 4 - 相关文章

2016年12月29日 - Meta-analysis assessed the efficacy and safety of the LDV-SOF with and ... LDV-SOF with and without RBV in treating HCV genotype 1 patients. Seven studies involving 2 626 patients with